TrovaGene Inc  

(Public, NASDAQ:TROVU)   Watch this stock  
Find more results for TROVU
50.00
May 11 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range     -
52 week 8.02 - 21.30
Open     -
Vol / Avg. 0.00/39.00
Mkt cap 267.29M
P/E     -
Div/yield     -
EPS -0.92
Shares 1.67M
Beta     -
Inst. own 417%
Aug 5, 2015
Q2 2015 Trovagene Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Jun 10, 2015
Trovagene Inc Annual Shareholders Meeting - 12:00PM EDT - Add to calendar
May 5, 2015
Q1 2015 Trovagene Inc Earnings Call
May 5, 2015
Q1 2015 Trovagene Inc Earnings Release
Mar 12, 2015
Q4 2014 Trovagene Inc Earnings Call
Mar 12, 2015
Q4 2014 Trovagene Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin -5650.45% -5112.96%
Operating margin -3818.03% -5334.13%
EBITD margin - -5250.32%
Return on average assets -77.02% -51.11%
Return on average equity -180.50% -99.85%
Employees 31 -
CDP Score - -

Address

11055 Flintkote Ave
SAN DIEGO, CA 92121-1220
United States - Map
+1-858-2175420 (Phone)
+1-858-2174768 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Trovagene, Inc. (TrovaGene) is a development-stage molecular diagnostic company that focuses on the development and commercialization of urine-based molecular diagnostic technology for use in disease detection and monitoring across a variety of medical disciplines. The Company’s internal focus is to leverage its urine-based molecular diagnostic platform to facilitate improvements in the field of oncology and external focus includes entering into collaborations to develop the Company’s technology in areas, such as infectious disease, transplant medicine and prenatal genetics. The Company’s San Diego-based CLIA-certified laboratory uses diagnostic technology for cancer mutation assays. Trovagene offers physicians control by tracking patient response to therapy with the choice of blood- or urine-based molecular tests that measures cancer-related gene mutations.

Officers and directors

Thomas H. Adams Jr., Ph.D. Independent Chairman of the Board
Age: 72
Bio & Compensation  - Reuters
Antonius P. Schuh Ph.D. Chief Executive Officer, Director
Age: 51
Bio & Compensation  - Reuters
Stephen L. Zaniboni Chief Financial Officer
Bio & Compensation  - Reuters
Matthew L. Posard Executive Vice President & Chief Commercial Officer
Age: 47
Bio & Compensation  - Reuters
Carl B. Feldbaum Esq Director
Age: 71
Bio & Compensation  - Reuters
Paul R. Billings M.D., Ph.D. Independent Director
Age: 62
Bio & Compensation  - Reuters
John P. Brancaccio Independent Director
Age: 67
Bio & Compensation  - Reuters
Gary S. Jacob Ph.D. Independent Director
Age: 68
Bio & Compensation  - Reuters
Rodney S. Markin M.D., Ph.D. Independent Director
Age: 58
Bio & Compensation  - Reuters